Not compatible with Internet Explorer
Not compatible with Internet Explorer
Not compatible with Internet Explorer
Investors
Kadimastem on Tel-Aviv Stock Exchange
For More Investors Info.
Kadimastem and Implant Therapeutics, Inc. Sign an Evaluation Agreement
June 8, 2022, 6:24:04 AM
Kadimastem Awarded Patent in Japan for AstroRx® For ALS and Drug Screening
May 30, 2022, 12:56:40 PM
Kadimastem Receives Grant for a Total Budget of $3.1 million from the Israeli Innovation Authority
March 3, 2022, 1:08:29 PM
Kadimastem Announces the Approval of a 4M NIS ($1.29M) Budget from the Israel Innovation Authority
December 13, 2021, 10:36:37 AM
Kadimastem Raises NIS 16.1 million ($5 million) In Private Placement
October 26, 2021, 5:52:59 AM
Successful Meeting with the FDA (INTERACT) Regarding IsletRx for the Treatment of Diabetes
October 12, 2021, 1:45:54 PM
Patent for Cell Selection of Beta Cells to Treat and Potentially Cure Diabetes was Granted in Japan
July 21, 2021, 12:46:30 PM
Kadimastem Announces Publication in Frontiers in Endocrinology of a Peer-Reviewed Article
May 11, 2021, 11:30:15 AM
Kadimastem Granted a Patent in Israel for the Treatment of ALS
March 9, 2021, 9:00:16 AM
Encouraging Results of Cohort B of its Phase 1/2a Clinical Trial of AstroRx® for ALS
December 15, 2020, 1:56:27 PM
Kadimastem Reports Positive Interim Results of Cohort B of its AstroRx® Phase 1/2a Clinical Trial in
August 3, 2020, 7:11:53 AM
Kadimastem Announces Promising Results of Cohort A of its Phase 1/2a Clinical Trial in ALS
July 27, 2020, 1:25:35 PM
Kadimastem Announces the Completion of Treatment for Cohort B
July 27, 2020, 1:25:54 PM
Successful Preclinical results of our Cell Therapy Treatment for Insulin-Dependent Diabetes
July 27, 2020, 1:27:08 PM
Kadimastem to Submit an Amendment of its ALS Phase 1/2a Clinical Trial Protocol
July 27, 2020, 1:28:11 PM
Kadimastem to Present at the 7th International Stem Cell Meeting, in Tel-Aviv
November 17, 2019, 2:10:12 PM
Kadimastem Announces Promising Interim Results of Cohort A of its Phase 1/2a Clinical Trial in ALS
July 27, 2020, 1:30:03 PM
Kadimastem receives Approval from the Ministry of Health of Israel to continue its trial of AstroRX®
April 18, 2019, 1:45:49 PM
Kadimastem Announces the Completion of Cell Transplantation of AstroRx® in ALS Patients for Cohort A
February 24, 2019, 7:48:37 AM
2019 Israel Innovation Authority Budget Approved for Kadimastem: NIS 13.6 M for ALS Project
February 17, 2019, 8:00:17 AM
Success for Kadimastem: 97% of Warrants (Series 4) Exercised for NIS 3.6M
November 14, 2018, 2:48:21 PM
Kadimastem and Defymed Awarded Grant for the Development of a Product for the Treatment of Diabetes
November 12, 2018, 2:48:44 PM